Data from the Phase 1 "HIV Cure" Study as published in Nature Medicine showed that Anktiva (N-803) stimulates latent HIV replication in CD4+ cells (the kick) and increases immune cell activation (the kill)
Activated CD4, CD8, and NK immune cells are necessary for finding and killing HIV-infected cells
No treatment-related serious adverse events were reported
Multiple Phase 1 and 2 trials with Anktiva in patients with HIV are ongoing
The need for this therapeutic approach is significant: Globally there are an estimated 38 million people living with HIV; in the US, with 1.2 million people living with HIV, the average annual cost of antiretrovirals is $36,000, while nearly $2 billion is spent on those therapies in developing countries
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.